These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
560 related articles for article (PubMed ID: 9214308)
21. NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding. Tugarinov V; Zvi A; Levy R; Hayek Y; Matsushita S; Anglister J Structure; 2000 Apr; 8(4):385-95. PubMed ID: 10801487 [TBL] [Abstract][Full Text] [Related]
22. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120. Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543 [TBL] [Abstract][Full Text] [Related]
23. NMR structure of the principal neutralizing determinant of HIV-1 displayed in filamentous bacteriophage coat protein. Jelinek R; Terry TD; Gesell JJ; Malik P; Perham RN; Opella SJ J Mol Biol; 1997 Mar; 266(4):649-55. PubMed ID: 9102458 [TBL] [Abstract][Full Text] [Related]
24. Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF. Vu HM; de Lorimier R; Moody MA; Haynes BF; Spicer LD Biochemistry; 1996 Apr; 35(16):5158-65. PubMed ID: 8611499 [TBL] [Abstract][Full Text] [Related]
25. NMR studies of V3 peptide complexes with antibodies suggest a mechanism for HIV-1 co-receptor selectivity. Sharon M; Rosen O; Anglister J Curr Opin Drug Discov Devel; 2005 Sep; 8(5):601-12. PubMed ID: 16159022 [TBL] [Abstract][Full Text] [Related]
26. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Kang CY; Luo L; Wainberg MA; Li Y Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338 [TBL] [Abstract][Full Text] [Related]
27. A disulfide-bound HIV-1 V3 loop sequence on the surface of human rhinovirus 14 induces neutralizing responses against HIV-1. Zhang A; Geisler SC; Smith AD; Resnick DA; Li ML; Wang CY; Looney DJ; Wong-Staal F; Arnold E; Arnold GF Biol Chem; 1999 Mar; 380(3):365-74. PubMed ID: 10223339 [TBL] [Abstract][Full Text] [Related]
28. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Stanfield RL; Gorny MK; Williams C; Zolla-Pazner S; Wilson IA Structure; 2004 Feb; 12(2):193-204. PubMed ID: 14962380 [TBL] [Abstract][Full Text] [Related]
30. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298 [TBL] [Abstract][Full Text] [Related]
31. [Conformation of the HIV-1 gp120 V3 loop. Structure functional analysis of the HIV-Haiti viral strain]. Andrianov AM Tsitologiia; 2006; 48(11):948-57. PubMed ID: 17233480 [TBL] [Abstract][Full Text] [Related]
32. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615 [TBL] [Abstract][Full Text] [Related]
33. Detailed analysis of the free and bound conformations of an antibody. X-ray structures of Fab 17/9 and three different Fab-peptide complexes. Schulze-Gahmen U; Rini JM; Wilson IA J Mol Biol; 1993 Dec; 234(4):1098-118. PubMed ID: 8263915 [TBL] [Abstract][Full Text] [Related]
34. Two-dimensional NMR studies of the interactions between a peptide of cholera toxin and monoclonal antibodies. Anglister J; Scherf T; Zilber B; Levy R Biopolymers; 1995; 37(6):383-9. PubMed ID: 8589243 [TBL] [Abstract][Full Text] [Related]
35. Structural mimicry and enhanced immunogenicity of peptide epitopes displayed on filamentous bacteriophage. The V3 loop of HIV-1 gp120. di Marzo Veronese F; Willis AE; Boyer-Thompson C; Appella E; Perham RN J Mol Biol; 1994 Oct; 243(2):167-72. PubMed ID: 7523682 [TBL] [Abstract][Full Text] [Related]
36. Structural studies of human HIV-1 V3 antibodies. Stanfield RL; Wilson IA Hum Antibodies; 2005; 14(3-4):73-80. PubMed ID: 16720977 [TBL] [Abstract][Full Text] [Related]
37. Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120. Kang CY; Hariharan K; Posner MR; Nara P J Immunol; 1993 Jul; 151(1):449-57. PubMed ID: 7686944 [TBL] [Abstract][Full Text] [Related]
38. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. Julien JP; Bryson S; Nieva JL; Pai EF J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005 [TBL] [Abstract][Full Text] [Related]
39. Solid-state NMR yields structural constraints on the V3 loop from HIV-1 Gp120 bound to the 447-52D antibody Fv fragment. Sharpe S; Kessler N; Anglister JA; Yau WM; Tycko R J Am Chem Soc; 2004 Apr; 126(15):4979-90. PubMed ID: 15080704 [TBL] [Abstract][Full Text] [Related]
40. Global and local structural properties of the principal neutralizing determinant of the HIV-1 envelope protein gp120. Andrianov AM J Biomol Struct Dyn; 1999 Feb; 16(4):931-53. PubMed ID: 10217460 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]